Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
Menu
My View
  • Edit
  • Add your favourite topics for quick access
Meet the Team
Ask The Analyst
Partnered Content
PDF Library
RSS Feeds
Subscribe
Advertising
PR Newswire
Report Store
UsernamePublicRestriction
Tags:

CryoCath clarification

This article was originally published in The Gray Sheet

  • News

Executive Summary

FDA-approved labeling for CryoCath's Freezor ablation catheter, PMA-approved April 22, includes directions for performing cryomapping prior to cryoablation of atrioventricular node re-entry tachycardia. However, the Freezor's instructions for use do not list cryomapping as a specific indication, as was reported in "The Gray Sheet" (April 28, p. 5)...
Table

View full table

Advertisement

Related Content

Medtech Insight
Advertisement
Tags:
UsernamePublicRestriction

Register

MT018313

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By